Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: A potential target treatment

Human Pathology

Volumn 44, Issue 2, 2013, Pages 218-225

  Peiró, Gloria ^a   Peiró, Francisca M ^b   Ortiz Martínez, Fernando ^a   Planelles, María ^c   Sánchez Tejada, Laura ^a   Alenda, Cristina ^a   Ceballos, Segundo ^a   Sánchez Payá, José ^a   Laforga, Juan B ^d  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL MARINA BAIXA   (Spain)

^c HOSPITAL VIRGEN DE LOS LIRIOS   (Spain)

^d Hospital de Dénia   (Spain)

Author keywords

Catenin; BRAF V600E; Endometrial carcinoma; MMR genes; MSI; mTOR; Outcome; PTEN

Indexed keywords

B RAF KINASE; BETA CATENIN; GENOMIC DNA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CELL NUCLEUS; CLINICAL FEATURE; CORRELATIONAL STUDY; CYTOPLASM; DNA EXTRACTION; ENDOMETRIUM CANCER; FEMALE; GENE LOSS; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOLECULAR MODEL; OUTCOME ASSESSMENT; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CARCINOMA, ENDOMETRIOID; DNA MISMATCH REPAIR; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; PHOSPHORYLATION; PROGNOSIS; PTEN PHOSPHOHYDROLASE; SIROLIMUS; TISSUE ARRAY ANALYSIS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84872681314     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.05.008     Document Type: Article

References (35)

1. G.F. Fleming Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant J Clin Oncol 25 2007 2983 2990 (Pubitemid 47123163)
2. J.V. Bokhman Two pathogenetic types of endometrial carcinoma Gynecol Oncol 15 1983 10 17 (Pubitemid 13194678)
3. G. Peiro, P. Lohse, D. Mayr, and J. Diebold Insulin-like growth factor-I receptor and PTEN protein expression in endometrial carcinoma. Correlation with bax and bcl-2 expression, microsatellite instability status, and outcome Am J Clin Pathol 120 2003 78 85 (Pubitemid 37046373)
4. G. Peiro, D. Mayr, P. Hillemanns, U. Lohrs, and J. Diebold Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome Mod Pathol 17 2004 227 287
5. A. Yeramian, G. Moreno-Bueno, and X. Dolcet Endometrial carcinoma: molecular alterations involved in tumor development and progression Oncogene 2012 10.1038/onc.2012.76 [Epub ahead of print]
6. M.A. Voss, R. Ganesan, and L. Ludeman Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer - a clinical and pathological evaluation Gynecol Oncol 124 2012 15 20
7. P.T. Bhaskar, and N. Hay The two TORCs and Akt Dev Cell 12 2007 487 502 (Pubitemid 46523652)
8. S. Darb-Esfahani, A. Faggad, and A. Noske Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro J Cancer Res Clin Oncol 135 2009 933 941
9. J.H. No, Y.T. Jeon, and I.A. Park Expression of mTOR protein and its clinical significance in endometrial cancer Med Sci Monit 15 2009 BR301 BR305
10. H. Wahl, S. Daudi, and M. Kshirsagar Expression of metabolically targeted biomarkers in endometrial carcinoma Gynecol Oncol 116 2010 21 27
11. C.H. Choi, J.S. Lee, and S.R. Kim Clinical significance of pmTOR expression in endometrioid endometrial carcinoma Eur J Obstet Gynecol Reprod Biol 153 2010 207 210
12. A. Delmonte, and C. Sessa Molecule-targeted agents in endometrial cancer Curr Opin Oncol 20 2008 554 559
13. D. Tsoref, and A.M. Oza Recent advances in systemic therapy for advanced endometrial cancer Curr Opin Oncol 23 2011 494 500
14. W. van Veelen, S.E. Korsse, L. van de Laar, and M.P. Peppelenbosch The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling Oncogene 30 2011 2289 2303
15. Silverberg SG, Kurman RJ, Nogales F. Tumours of the uterine corpus. In: Tavassoli FA, Devilee P (eds). Pathology and genetics of tumours of the breast and female genital organs. IARC Press: Lyon 2003. p. 217-28.
16. N. Suraweera, A. Duval, and M. Reperant Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR Gastroenterology 123 2002 1804 1811 (Pubitemid 35408304)
17. G. Peiro, J. Diebold, and P. Lohse Microsatellite instability, loss of heterozygosity, and loss of hMLH1 and hMSH2 protein expression in endometrial carcinoma Hum Pathol 33 2002 347 354 (Pubitemid 34461470)
18. S. Benlloch, A. Paya, and C. Alenda Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology J Mol Diagn 8 2006 540 543 (Pubitemid 44774151)
19. Q. Shen, M.L. Stanton, and W. Feng Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma Int J Clin Exp Pathol 4 2010 13 21
20. Y. Yoshida, T. Kurokawa, Y. Horiuchi, Y. Sawamura, A. Shinagawa, and F. Kotsuji Localisation of phosphorylated mTOR expression is critical to tumour progression and outcomes in patients with endometrial cancer Eur J Cancer 46 2010 3445 3452
21. L. Catasus, E. D'Angelo, C. Pons, I. Espinosa, and J. Prat Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations Mod Pathol 23 2010 694 702
22. D.R. Alessi, K. Sakamoto, and J.R. Bayascas LKB1-dependent signaling pathways Annu Rev Biochem 75 2006 137 163 (Pubitemid 44118029)
23. C.M. Contreras, S. Gurumurthy, and J.M. Haynie Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas Cancer Res 68 2008 759 766 (Pubitemid 351206752)
24. J.I. Risinger, K. Hayes, and G.L. Maxwell PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics Clin Cancer Res 4 1998 3005 3010 (Pubitemid 29001474)
25. H.J. Mackay, S. Gallinger, and M.S. Tsao Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG) Eur J Cancer 46 2010 1365 1373
26. P. Athanassiadou, P. Athanassiades, and D. Grapsa The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study Int J Gynecol Cancer 17 2007 697 704 (Pubitemid 46744009)
27. K. Uegaki, Y. Kanamori, and J. Kigawa PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma Oncol Rep 14 2005 389 392
28. A. Steinbakk, A. Malpica, and A. Slewa Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma Mod Pathol 24 2011 1262 1271
29. I. Zighelboim, P.J. Goodfellow, and F. Gao Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type J Clin Oncol 25 2007 2042 2048 (Pubitemid 46972789)
30. D. Black, R.A. Soslow, and D.A. Levine Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma J Clin Oncol 24 2006 1745 1753 (Pubitemid 46622146)
31. G. Moreno-Bueno, C. Sanchez-Estevez, J. Palacios, D. Hardisson, and T. Shiozawa Low frequency of BRAF mutations in endometrial and in cervical carcinomas Clin Cancer Res 12 2006 3865 [author reply 3865-6] (Pubitemid 44000271)
32. M. Kawaguchi, M. Yanokura, and K. Banno Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer Int J Oncol 34 2009 1541 1547
33. Y.Z. Feng, T. Shiozawa, and T. Miyamoto BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression Clin Cancer Res 11 2005 6133 6138 (Pubitemid 41262939)
34. G. Moreno-Bueno, D. Hardisson, and C. Sanchez Abnormalities of the APC/beta-catenin pathway in endometrial cancer Oncogene 21 2002 7981 7990 (Pubitemid 35430609)
35. N. Bansal, V. Yendluri, and R.M. Wenham The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies Cancer Control 16 2009 8 13